martes, 12 de mayo de 2020

Disaster Lit® Database Daily Updates | COVID-19

Disaster Lit® Database Daily Updates

Disaster Information and Emergency Response



05/10/2020 12:00 AM EDT

Source: World Health Organization (WHO). Published: 5/10/2020. This five-page document provides an overview of surveillance strategies that Member States should consider as part of comprehensive national surveillance for COVID-19. It emphasizes the need to adapt and reinforce existing national systems where appropriate and to scale up surveillance capacities as needed. (PDF)
05/10/2020 12:00 AM EDT

Source: World Health Organization (WHO). Published: 5/10/2020. This seven-page document provides guidance on how to establish contact tracing capacity for the control of COVID-19. When systematically applied, contact tracing will break the chains of transmission of an infectious disease and is thus an essential public health tool for controlling infectious disease outbreaks. (PDF)
05/07/2020 12:00 AM EDT

Source: U.S. Food and Drug Administration (FDA). Published: 5/7/2020. This eight-page letter, revised on May 7, 2020, updates the April 3, 2020, EUA for certain product classifications for imported disposable filtering facepiece respirators that are manufactured in China and not approved by the Centers for Disease Control and Prevention’s National Institute of Occupational Safety and Health (NIOSH). It was revised for clarity and to address concerns about sub-standard products, which includes revising the third criterion for eligibility and adding a process for removal from Appendix A. (PDF)
05/07/2020 12:00 AM EDT

Source: U.S. Food and Drug Administration (FDA). Published: 5/7/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of decontaminated, compatible N95 respirators. These compatible N95 respirators have been decontaminated using the Duke Decontamination System with Hydrogen Peroxide Vapor, which received an Emergency Use Authorization from the Food and Drug Administration on May 7, 2020. (PDF)
05/07/2020 12:00 AM EDT

Source: U.S. Food and Drug Administration (FDA). Published: 5/7/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the Rutgers Clinical Genomics Laboratory TaqPath SARS-CoV-2 Assay, which received an Emergency Use Authorization from the Food and Drug Administration on May 7, 2020. The Rutgers Clinical Genomics Laboratory TaqPath SARS-CoV-2 Assay is authorized for use on respiratory specimens from individuals suspected of coronavirus disease 2019 (COVID-19) by their healthcare provider. (PDF)
05/07/2020 12:00 AM EDT

Source: U.S. Food and Drug Administration (FDA). Published: 5/7/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the Quick SARS-CoV-2 rRT-PCR Kit, which received an Emergency Use Authorization from the Food and Drug Administration on May 7, 2020. The Quick SARS-CoV-2 rRT-PCR Kit is authorized for use on respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
05/07/2020 12:00 AM EDT

Source: American Society for Healthcare Engineering (ASHE). Published: 5/7/2020. This web page provides answers to frequently asked questions about COVID-19 for these topics: HVAC/Negative Pressure, Construction, Life Safety/Staff Safety, Disinfection, Personal Protective Equipment, Filtration, and Alternate Care Sites. (Text)
05/07/2020 12:00 AM EDT

Source: U.S. Senate, Committee on Health, Education, Labor, and Pensions. Published: 5/7/2020. This three-hour, six-minute Congressional hearing features witnesses who discuss how the National Institutes of Health (NIH) and its funded scientists across the country are harnessing innovation to prevent, diagnose, and treat the novel coronavirus (COVID-19) currently plaguing the nation, including work on testing, therapeutics, vaccines, and private-public partnerships. They also discuss efforts to develop appropriate and effective medical countermeasures to prevent infection and test and treat those with or suspected of having COVID-19. (Video or Multimedia)
05/07/2020 12:00 AM EDT

Source: National Academy of Medicine (NAM). Published: 5/7/2020. The key objectives of this one-hour, 28-minute webinar include describing the existing clinician burnout crisis prior to the COVID-19 pandemic and the goals of the Action Collaborative on Clinician Well-Being and Resilience; identifying the critical needs and priorities to support the well-being of clinicians, including those in their formative years of training, during the COVID-19 era; and spotlighting programs, resources, and leadership efforts currently underway to address and monitor the acute and long-term mental health and well-being of clinicians on the frontlines of COVID-19. It was held in partnership with the Accreditation Council for Graduate Medical Education, American Hospital Association, American Medical Association, and the Association of American Medical Colleges. (Video or Multimedia)
05/06/2020 12:00 AM EDT

Source: U.S. Food and Drug Administration (FDA). Published: 5/6/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the OPTI SARS-CoV-2 RT PCR Test, which received an Emergency Use Authorization from the Food and Drug Administration on May 6, 2020. The OPTI SARS-CoV-2 RT PCR Test is authorized for use on respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
05/06/2020 12:00 AM EDT

Source: U.S. Food and Drug Administration (FDA). Published: 5/6/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the Sherlock™ CRISPR SARS-CoV-2 kit, which received an Emergency Use Authorization from the Food and Drug Administration on May 6, 2020. The Sherlock™ CRISPR SARS-CoV-2 kit is authorized for use on respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
05/06/2020 12:00 AM EDT

Source: U.S. Food and Drug Administration (FDA). Published: 5/6/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the SARS-COV-2 R-GENE® test, which received an Emergency Use Authorization from the Food and Drug Administration on May 6, 2020. The SARS-COV-2 R-GENE® test is authorized for use on respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
05/06/2020 12:00 AM EDT

Source: Center for Health Security [Johns Hopkins University, Bloomberg School of Public Health]. Published: 5/6/2020. This operational toolkit has been developed to help business owners who are considering reopening or expanding their operations to determine their establishments’ risk of transmission of COVID-19 and how to reduce it. It contains three parts: an instruction manual; a business risk worksheet; and an assessment calculator. (Text)
05/06/2020 12:00 AM EDT

Source: U.S. House of Representatives, Committee on Appropriations. Published: 5/6/2020. In this two-hour, 43-minute Congressional hearing, witnesses discuss views of the path forward for responding to the COVID-19 pandemic, and based on 30 years of fighting epidemics -- including the Centers for Disease Control and Prevention’s response to Ebola -- propose a new approach to bring stability and security to the efforts to keep Americans safer from epidemics. (Video or Multimedia)
05/05/2020 12:00 AM EDT

Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 5/5/2020. This web page discusses how providing care to others during the COVID-19 pandemic can lead to stress, anxiety, fear, and other strong emotions. It provides guidance on how to recognize what stress looks like, take steps to build your resilience and cope with stress, and know where to go if you need help. (Text)
05/04/2020 12:00 AM EDT

Source: Institute for Risk and Disaster Reduction [University College London] (UCL IRDR). Published: 5/4/2020. The purpose of this 41-page report is to provide a systematic, if incomplete, record of the issues connected with the COVID-19 pandemic in order to improve the basis for future emergency planning. Like all large disasters, COVID-19 involves cascading consequences. These need to be factored into future emergency planning scenarios. (PDF)
05/03/2020 12:00 AM EDT

Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 5/3/2020. This interim guidance is for veterinarians and their staff who may be treating or advising on companion animal medical care during the COVID-19 pandemic. Veterinary facilities have unique characteristics that warrant unique infection control considerations. (Text)
05/01/2020 12:00 AM EDT

Source: American Hospital Association (AHA). Published: 5/2020. This four-page document provides some ways to help care for and support health care heroes during the COVID-19 pandemic, which presents unique mental health stress points for health care workers, such as putting their families and colleagues at risk for exposure to the virus, making difficult decisions about how to conserve supplies and prioritize treatment, working extended shift hours, and confronting an unimaginable death toll. (PDF)
05/01/2020 12:00 AM EDT

Source: National Council for Prescription Drug Programs (NCPDP). Published: 5/2020. This 63-page document has been updated with specific guidance related to pharmacist-led COVID-19 testing, as well as other updates that provide standards-based guidance and resources to the pharmacy industry during a declared national emergency such as natural disaster or pandemic. (PDF)
04/29/2020 12:00 AM EDT

Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 4/29/2020. To facilitate implementation of World Health Organization COVID-19 technical guidance on infection prevention and control (IPC) activities for countries, the Centers for Disease Control and Prevention has developed operational considerations to help contain and prevent COVID-19 in healthcare facilities in non-U.S. settings. The documents on this page were created for healthcare facilities with limited resources (such as staff shortages and supply shortages), particularly in low- and middle-income countries. (Text)
04/08/2020 12:00 AM EDT

Source: Alliance for Child Protection in Humanitarian Action. Published: 4/8/2020. This 13-page technical note, published with UNICEF, aims to provide detaining authorities with key information and steps to respond to COVID-19, including by instituting a moratorium on new children entering detention facilities; releasing all children who can be safely released; and protecting the health and well-being of any children who must remain in detention. (PDF)
03/30/2020 12:00 AM EDT

Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 3/30/2020. This web page provides answers to frequently asked questions for administrators of retirement communities and independent living facilities about COVID-19 preparedness and planning, and if there is a case in the facility. (Text)



No hay comentarios:

Publicar un comentario